Matrix Surgical USA

Executive Summary

Matrix Surgical USA is a privately held medical device company specializing in porous high-density polyethylene (PHDPE) implants for craniomaxillofacial reconstructive and aesthetic surgery. Headquartered in Atlanta, Georgia, and founded in 2008, the company markets its flagship OMNIPORE® Surgical Implants, which include over 80 standard anatomical configurations and patient-specific solutions. The implants are FDA-cleared and CE-marked, with distribution across more than 35 countries. Matrix Surgical USA leverages a proprietary material technology to offer implants that promote tissue integration and reduce complications, positioning the company as a niche player in the craniomaxillofacial reconstruction market. With a focus on innovation and customization, the company serves a diverse range of surgeons and hospitals globally, though it remains relatively small compared to larger orthopedic and medical device firms. Ongoing efforts to expand its product portfolio and geographic reach underpin its growth strategy, while the lack of public financial data makes precise valuation challenging.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation OMNIPORE facial implants with enhanced porosity70% success
• Q4 2026Entry into the Asia-Pacific market via NMPA (China) or PMDA (Japan) regulatory approval50% success
• TBDStrategic partnership with a larger medical device company for distribution or co-development30% success